Saxenda Pricing: How Much Does It Cost and Who Covers It?
What is the typical list price for Saxenda?
The list price of Saxenda, a prescription medication used to treat obesity and weight-related conditions, can vary depending on the dosage, quantity, and location. According to [1] DrugPatentWatch.com, as of 2023, the typical U.S. wholesale price for a single dosage of Saxenda is around $1,300.
Does insurance cover Saxenda?
Saxenda is a prescription medication, and insurance coverage can vary depending on the plan and insurance provider. Some employers, unions, and Medicare Advantage plans may cover Saxenda, but patients should check with their insurance provider for specific information about coverage and out-of-pocket costs.
Do discount programs or patient assistance programs help cover the cost?
While insurance coverage can help with Saxenda costs, patients with high deductibles or co-payments may still face significant out-of-pocket expenses. Saxenda does offer a Patient Savings Program, which can provide discounted prescriptions, free co-pay assistance, or both, depending on eligibility [2]. Patients can check with the Saxenda website or consult with their doctor's office for more information.
How does Saxenda pricing compare to other obesity medications?
Saxenda pricing is generally considered higher than some other obesity medications, such as those in the GLP-1 receptor agonist class [3]. However, the exact cost comparison depends on the specific medication and dosage.
When does patent exclusivity for Saxenda expire?
The U.S. patent for Saxenda, held by Novo Nordisk, is set to expire in 2034, although patent expiration can be extended through various mechanisms [4]. As a result, generic or biosimilar alternatives to Saxenda may become available at lower prices after patent expiration.
Sources:
[1] DrugPatentWatch.com. Saxenda (liraglutide) - Price, Patent, Uses, and More.
[2] Saxenda Patient Savings Program.
[3] Obesity medication prices in the United States: a systematic review.
[4] LexisNexis PatentSphere. Novo Nordisk A/S - Saxenda patent overview.